ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Telmisartan

Also written as “telmisartan”, “CKD-828, D097, D337” and “Telmisartan 40 mg”.

Its studies are mostly in Hypertension · Essential Hypertension · Diabetic Nephropathies · Hypercholesterolemia · Hyperlipidemias, led by 15 companies.

Drug pageTelmisartan: every studyMany companies study it; this page follows only the 130 they lead. All 177 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since May 2, 2002130 company-led studies, 4 open or runningNext primary completion: Apr 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim900 open or runningphase 4since May 2, 2002May 2, 2002none ahead
Chong Kun Dang Pharmaceuticalits history only122 open or runningphase 4since Mar 9, 2023May 20, 2010none ahead
Yuhanits history only81 open or runningphase 4since Nov 10, 2016May 29, 2014none ahead
IlDong Pharmaceuticalits history only40 open or runningphase 3since Mar 5, 2014Mar 5, 2014none ahead
Jeil Pharmaceuticalits history only30 open or runningphase 3since Mar 8, 2017Mar 9, 2015none ahead
Daewon Pharmaceuticalits history only20 open or runningphase 3since Oct 12, 2016Oct 12, 2016none ahead
George Medicines PTYits history only20 open or runningphase 3since Aug 15, 2020Aug 15, 2020none ahead
HK inno.Nits history only20 open or runningphase 1since Aug 25, 2021Aug 25, 2021none ahead
Daewoong Pharmaceuticalits history only10 open or runningphase 1since Mar 4, 2013Mar 4, 2013none ahead
DongKoo Bio & Pharmaits history only10 open or runningphase 1since Feb 8, 2018Feb 8, 2018none ahead

Also a collaborator on its studies: Linical Korea, GlaxoSmithKline and Bayer.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Boehringer Ingelheim only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 7 studies since Mar 11, 2009.

  1. Jan 28, 2011Phase 3 study in HypertensionNCT01286558 · 225 enrolled · Japan
  2. Apr 26, 2011Phase 1 study in HealthyNCT01344629 · 64 enrolled · Japan
  3. Jun 20, 20143 phase 4 studies in HypertensionNCT02172586, NCT02177461, NCT02178306
  4. Jun 25, 20149 phase 3 studies in HypertensionNCT02175355, NCT02177500, NCT02177487 and 6 more
  5. Jul 7, 20142 phase 3 studies in HypertensionNCT02183701, NCT02206659
  6. Jul 7, 20145 phase 1 studies in HealthyNCT02183675, NCT02187536, NCT02187523 and 2 more
  7. Jul 9, 20142 phase 2 studies in HypertensionNCT02187497, NCT02187484
  8. Jul 24, 20142 phase 4 studies in HypertensionNCT02200653, NCT02200640
  9. Aug 12, 20144 phase 1 studies in HealthyNCT02215005, NCT02214992, NCT02214979 and 1 more
  10. Sep 16, 20143 phase 4 studies in HypertensionNCT02242812, NCT02242370, NCT02242318
  11. Sep 16, 2014Phase 2 study in HypertensionNCT02242344 · 77 enrolled
  12. Oct 6, 201417 phase 1 studies in HealthyNCT02259829, NCT02259816, NCT02259803 and 14 more
  13. Oct 8, 20142 phase 4 studiesNCT02260089, NCT02261116
  14. Oct 20, 2014Phase 3 study in HypertensionNCT02269176 · 330 enrolled

TargetBeta

AGTR1 →read by rule
“Type-1 angiotensin II receptor antagonist”ChEMBL 37, by rule

Other programs on AGTR1

ProgramCompanyFurthest phaseStudies
ValsartanruleNovartisphase 4145
LosartanruleOrganonphase 458
azilsartan medoxomilruleTakedaphase 425
sparsentanruletravere-therapeutics-incphase 49

Studies

The newest 60 of 90 Boehringer Ingelheim leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT02276391Healthy1CompletedOct 200864
NCT02269176Hypertension3CompletedJan 2001330
NCT02263989Healthy1CompletedApr 200730
NCT02262858Healthy1CompletedOct 200568
NCT02262793Healthy1CompletedJul 200424
NCT02262780Healthy1CompletedFeb 15, 200420
NCT02262650Healthy1CompletedMay 200424
NCT02262624Healthy1CompletedFeb 200536
NCT02262598Healthy1CompletedOct 200430
NCT02262585Healthy1CompletedAug 200230
NCT02262572Healthy1CompletedAug 200324
NCT02262559Healthy1CompletedAug 200230
NCT02261129Healthy1CompletedDec 200864
NCT02261116Healthy4CompletedAug 200224
NCT02261064Healthy1CompletedFeb 200932
NCT02260089Hypertension4CompletedJul 2002134
NCT02259829Healthy1CompletedNov 200784
NCT02259816Healthy1CompletedAug 200638
NCT02259803Healthy1CompletedNov 200730
NCT02259790Healthy1CompletedAug 200730
NCT02242812Hypertension4TerminatedOct 200424
NCT02242370Hypertension4CompletedNov 20003,045
NCT02242344Hypertension2CompletedSep 200777
NCT02242318Hypertension4CompletedSep 2002440
NCT02218684Healthy1CompletedNov 199827
NCT02215005Healthy1CompletedSep 200742
NCT02214992Healthy1CompletedJun 200784
NCT02214979Healthy1CompletedJun 200784
NCT02206659Hypertension3CompletedFeb 200120
NCT02203500Healthy1CompletedJan 199926
NCT02200653Hypertension4CompletedFeb 2001387
NCT02200640Hypertension4CompletedDec 2000333
NCT02193308Healthy1CompletedNov 200784
NCT02187536Healthy1CompletedMay 200016
NCT02187523Healthy1CompletedDec 199932
NCT02187497Hypertension2CompletedSep 199893
NCT02187484Hypertension2CompletedAug 199923
NCT02183701Hypertension3CompletedDec 1998715
NCT02183675Healthy · Japan1CompletedOct 201436
NCT02178306Hypertension4CompletedApr 200282
NCT02177500Hypertension3CompletedMay 2000327
NCT02177487Hypertension3CompletedJan 2000100
NCT02177461Hypertension4CompletedAug 2002374
NCT02177448Hypertension3CompletedSep 1999225
NCT02177435Hypertension3CompletedSep 1999491
NCT02177422Hypertension3CompletedNov 1999489
NCT02177409Hypertension3CompletedDec 1998431
NCT02177396Hypertension3CompletedDec 1998426
NCT02176499Hypertension3CompletedJul 199926
NCT02175355Hypertension3CompletedAug 20001,039
NCT02172586Hypertension4CompletedJan 2002363
NCT01344629Healthy · Japan1CompletedJul 201164
NCT01286558Hypertension · Japan3CompletedSep 2011225
NCT01278797Hypertension · Canada1CompletedFeb 201128
NCT01222520Hypertension · Japan3CompletedJun 2011174
NCT01204398Hypertension · China3CompletedJul 201127
NCT01181011Healthy · China1CompletedNov 201028
NCT01134393Hypertension · Germany, Italy, Mexico and more3CompletedMay 2011502
NCT01103960Hypertension · China, Malaysia, Philippines3CompletedAug 2011324
NCT00860262Hypertension · United States, Bulgaria, Czech Republic and more3CompletedDec 2009858

How it is read

Names in the registry

  • “Telmisartan”, 38 entries
  • “telmisartan”, 7 entries
  • “CKD-828, D097, D337”, 6 entries
  • “Telmisartan 40 mg”, 6 entries
  • “Low dose of telmisartan”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.